GlassScriptPhysician profile
Brian J Beesley
NPI 1447213970
$1,384,853.14
in general payments reported to CMS, 2019-2025
52 companies · $183K in 2025
The $183K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250K · 2020: $175K · 2021: $150K · 2022: $235K · 2023: $181K · 2024: $211K · 2025: $183K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $448K · Travel and Lodging: $62K · Food and Beverage: $20K · Consulting Fee: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Honoraria: $14K · Education: $52.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $448,123.00 |
| Travel and Lodging | $61,941.46 |
| Food and Beverage | $19,694.26 |
| Consulting Fee | $15,700.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,067.68 |
| Honoraria | $13,700.00 |
| Education | $52.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $730,596.89 | 2019-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $252,539.36 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Janssen Products, LP | $211,212.52 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $92,377.79 | 2019-2025 | Egrifta Sv, Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $44,376.99 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Napo Pharmaceuticals INC | $30,701.89 | 2019-2025 | Mytesi |
| Abbvie INC. | $15,541.01 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Janssen Scientific Affairs, LLC | $1,974.92 | 2019-2023 | Symtuza |
| Glaxosmithkline, LLC. | $1,299.88 | 2019-2023 | Shingrix, Arexvy |
| Janssen Biotech, INC. | $1,029.32 | 2019-2023 | Symtuza |
| Bayer Healthcare Pharmaceuticals INC. | $481.87 | 2022-2025 | |
| Novo Nordisk INC | $310.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $289.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.47 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Lilly USA, LLC | $189.71 | 2020-2025 | Mounjaro, Emgality, Jardiance |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Beesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.